ShareValue scores for SBTX.LSE: Valuation 56, Quality 37, Growth 64, Health 42.
SBTX.LSELSE
SkinBioTherapeutics PLC
£0.04
(-5.88%)
Updated
SBTX.LSELSE
SkinBioTherapeutics PLC
Updated
Pulse
Pulse
Fundamental Rating
Value Trap Risk
If P/E met sector median
Rating
Trap Risk
P/E to median
vs London-listed Healthcare stocks
Company Details
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with Croda Plc for the development of SkinBiotix as an active ingredient for the skicare and cosmetic industry. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Driffield, the United Kingdom.
Score Analysis
AI Investment Thesis
SkinBioTherapeutics PLC looks fairly valued against London-listed Healthcare stocks, with P/B of 1.54 lower than 68% of peers and P/S of 2.35 lower than 56% of peers.
Financial health is the decisive weakness: cash fell to £1.5m at 30 June 2026 against a £1.6m adjusted EBITDA loss, so the 0.06 debt-to-equity ratio understates real funding risk.
On 10 November 2026 the company appointed Gill Whitty-Collins, ex-P&G Beauty senior vice president, as non-executive director, adding brand and commercial experience.